Regeneron to Report Q1 Earnings: What's in Store for the Stock?

Core Viewpoint - Regeneron Pharmaceuticals is expected to report first-quarter 2025 results on April 29, 2025, with revenue estimates at $3.25 billion and earnings at $8.76 per share. The company has a mixed earnings surprise history, with an average surprise of 3.23% over the last four quarters [1][2]. Financial Performance - The Earnings Surprise Prediction Model indicates a negative Earnings ESP of -0.94%, suggesting a lower likelihood of an earnings beat this quarter [3]. - The Zacks Rank for Regeneron is currently 4 (Sell), indicating a bearish outlook [3]. Product Sales Overview - Eylea, Regeneron's leading drug, is facing sales pressure due to competition from Vabysmo, with expected sales in the U.S. pegged at $1.2 billion for the first quarter [4][5][6]. - The introduction of Eylea HD is anticipated to have positively impacted total Eylea franchise sales due to strong demand [6]. - Dupixent is another significant revenue driver, with sales estimates at $3.7 billion, bolstered by strong prescription trends and recent label expansions [7][8]. - Libtayo's sales are projected at $346 million, driven by increased demand in non-melanoma skin indications and lung cancer treatments [10]. Regulatory and Pipeline Updates - Regeneron received European Commission approval for odronextamab, enhancing its oncology portfolio [11]. - The FDA approved a label expansion for Dupixent, while a complete response letter was issued regarding the extended dosing intervals for Eylea HD [14][15][16]. - The FDA accepted a supplemental biologics license application for Eylea HD, with a target action date set for August 19, 2025 [17]. Shareholder Returns - In February 2025, Regeneron initiated a quarterly cash dividend program at $0.88 per share and authorized a $3.0 billion share repurchase program, totaling approximately $4.5 billion [13]. Market Performance - Regeneron's shares have declined by 21.1% year-to-date, compared to a 7.8% decline in the industry [18].